Publications by authors named "A Caldara"
Estrogen receptor (ER)-positive breast cancer (BC) is the most common BC subtype. Endocrine therapy (ET) targeting ER signaling still remains the mainstay treatment option for hormone receptor (HR)-positive BC either in the early or in advanced setting, including different strategies, such as the suppression of estrogen production or directly blocking the ER pathway through SERMs-selective estrogen receptor modulators-or SERDs-selective estrogen receptor degraders. Nevertheless, the development of de novo or acquired endocrine resistance still remains challenging for oncologists.
View Article and Find Full Text PDFThe combination of atezolizumab and nab-paclitaxel is recommended in the EU as first-line treatment for PD-L1-positive metastatic triple-negative breast cancer (mTNBC), based on the results of phase III IMpassion130 trial. However, 'real-world' data on this combination are limited. The ANASTASE study (NCT05609903) collected data on atezolizumab plus nab-paclitaxel in PD-L1-positive mTNBC patients enrolled in the Italian Compassionate Use Program.
View Article and Find Full Text PDFArticle Synopsis
- Endocrine therapy (ET) is a primary treatment for estrogen receptor-positive breast cancer, using tools like aromatase inhibitors and medications such as tamoxifen to block estrogen signaling.
- Resistance to ET, either from the start or after treatment, is a major reason for therapy failure and cancer progression, largely due to changes in the ESR1 gene.
- New oral selective estrogen receptor degraders are being developed that can effectively target and overcome these resistance issues by reducing ER protein levels and blocking estrogen's effects, offering hope for better treatment outcomes.